Table 4.

Longitudinal model: time-fixed and time-varying predictors of failure to apply T2T-LDA during 2-year followup of the RA BIODAM cohort.

Variables	Univariable OR (95% CI), N = 544–571	Univariable p	Multivariable OR (95% CI), N = 554
Age, yrs	1.01 (1.00–1.01)	0.096	^¥
Sex, female	1.01 (0.81–1.25)	0.963	^†
Disease duration, yrs	1.00 (0.99–1.02)	0.528	^†
Education, yrs	0.97 (0.95–1.00)	0.032	^¥
No. comorbidities	1.17 (1.08–1.26)	< 0.001	1.11 (1.03–1.20)
Current smoker	1.24 (1.01–1.53)	0.041	1.26 (1.03–1.53)
Type of center, academic	0.82 (0.67–1.00)	0.050	0.81 (0.68–0.98)
RF positivity	0.63 (0.51–0.77)	< 0.001	^*
ACPA positivity	0.57 (0.47–0.70)	< 0.001	^*
RF and/or ACPA positivity	0.58 (0.46–0.73)	< 0.001	0.66 (0.53–0.82)
PtGA (0–10) ^‡	1.11 (1.08–1.14)	< 0.001	^¥
PGA (0–10) ^‡	1.06 (1.03–1.10)	< 0.001	^¥
Swollen joint count (0–44) ^‡	1.00 (0.98–1.02)	0.962	^†
Tender joint count (0–53) ^‡	1.03 (1.03–1.04)	< 0.001	1.02 (1.01–1.03)
ESR, mm/h ^‡	1.01 (1.00–1.01)	0.013	^¥
CRP, mg/l ^‡	1.00 (0.99–1.00)	0.453	^†
HAQ ^‡	1.43 (1.26–1.61)	< 0.001	^¥
No. previous csDMARD	1.02 (0.94–1.11)	0.622	^†
Previous treatment with any csDMARD	1.10 (0.91–1.33)	0.318	^†

↵† Not selected from the univariable analysis (p > 0.20).
↵¥ Not significant in the multivariable analysis (p > 0.05).
↵‡ Modeled as time-varying.
↵* RF or ACPA positivity entered into multivariate model. Country added as a covariate in all univariable models and in the final multivariable model. Final model also adjusted for type of treatment (csDMARD and/or bDMARD). Values in bold face are statistically significant. T2T: treat-to-target; LDA: low disease activity; RA: rheumatoid arthritis; RF: rheumatoid factor; ACPA: anticitrullinated protein antibody; SKATe6055PtGA: patient’s global assessment; PGA: physician’s global assessment; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; HAQ: Health Assessment Questionnaire; csDMARD: conventional synthetic disease-modifying antirheumatic drug; bDMARD: biological DMARD.